CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B‐cell lymphoma

Abstract De novo CD5‐positive diffuse large B‐cell lymphoma (CD5+ DLBCL) is increasingly recognized as a distinct pathologic phenomenon with a specific clinical picture. However, CD5+ DLBCL has not been studied on a large scale in China. In this study, we show that CD5+ DLBCL occurs at a low frequency (9.2%). Comparison of clinical characteristics of CD5+ vs CD5− DLBCL showed that CD5+ DLBCL was more frequently elderly (>60 years) and had B symptoms, high‐performance status, stage III‐IV, an IPI score >2 and bone marrow involvement. Patients with CD5+ DLBCL had tumours with a higher prevalence of BCL‐2 and p53 overexpression than CD5− DLBCL. Patients with CD5+ DLBCL had inferior progression‐free survival (PFS) and overall survival (OS) than did patients with CD5− DLBCL. For CD5+ DLBCL, the patients who were treated with rituximab showed significantly better PFS and OS than those treated without rituximab. However, patients treated with RCHOP showed similar PFS and OS when compared with the group treated with intensive therapy. In addition, patients with p53 and CD5 co‐expression had the worst PFS and OS. In conclusion, CD5+ DLBCL was associated with unfavorable clinicopathologic variables and with inferior survival. CD5+ DLBCL has a high frequency of p53 overexpression, and CD5 augments the negative effect of p53 overexpression in DLBCL.